AURXOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Nuo Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.26−0.04 (-3.08%)
Close on Oct 19, 2026
- Market cap
- $60.99M
- P/E (TTM)
- –
- Dividend yield
- –
Nuo Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Surgical & Medical Instruments & Apparatus companies for comparison
Valuation
| Measure | Nuo Therapeutics | Industry median |
|---|---|---|
| Market Cap | $61.03M | $230.55M |
| Enterprise Value | $60.58M | $202.97M |
| PS Ratio | 11.74 | 3.11 |
Enterprise value
| Measure | Nuo Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 11.65 | 2.92 |
Income (trailing twelve months)
| Measure | Nuo Therapeutics | Industry median |
|---|---|---|
| Revenue | $5.20M | $102.39M |
| Gross Profit | $3.33M | $60.36M |
| Operating Income | -$1.73M | -$4.31M |
| Net Income | -$2.01M | -$6.57M |
| EBITDA | -$1.73M | -$1.98M |
| EPS (Diluted) | -$0.04 | -$0.07 |
Margins
| Measure | Nuo Therapeutics | Industry median |
|---|---|---|
| Gross Margin | 64.1% | 55.1% |
| Operating Margin | -33.3% | -6.04% |
| Profit Margin | -38.7% | -10.5% |
| EBITDA Margin | -33.3% | -2.67% |
| FCF Margin | -47.1% | -0.30% |
Returns
| Measure | Nuo Therapeutics | Industry median |
|---|---|---|
| Return on Assets (ROA) | -101.0% | -13.3% |
| Return on Capital Employed (ROCE) | -161.6% | -9.07% |
Growth
| Measure | Nuo Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 166.6% | 8.85% |
| Revenue Growth (3Y CAGR) | 209.1% | 7.08% |
Balance sheet
| Measure | Nuo Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $449.33K | $37.33M |
| Net Cash (Debt) | $449.33K | $3.92M |
| Net Cash Per Share | $0.01 | $0.28 |
| Equity (Book Value) | -$1.54M | $57.36M |
| Book Value Per Share | -$0.03 | $2.81 |
| Tangible Book Value | -$1.54M | $10.71M |
| Working Capital | $439.43K | $54.64M |
Financial position
| Measure | Nuo Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 1.28 | 2.50 |
| Quick Ratio | 1.04 | 1.54 |
Cash flow (trailing twelve months)
| Measure | Nuo Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$2.15M | -$653.46K |
| Capital Expenditures | -$297.08K | -$3.69M |
| Free Cash Flow | -$2.45M | -$835.02K |
| FCF Per Share | -$0.05 | -$0.02 |
Efficiency
| Measure | Nuo Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 2.61 | 0.59 |
| Inventory Turnover | 8.58 | 2.21 |
| Revenue Per Employee | $520.00K | $322.57K |
| Profits Per Employee | -$201.25K | -$51.88K |
| Employee Count | 10 | 185 |
Dividends and yields
| Measure | Nuo Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -3.30% | -6.91% |
| FCF Yield | -4.01% | -0.56% |
Shares
| Measure | Nuo Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 48,433,800 | 44,856,700 |
| Shares Change (YoY) | 3.15% | 3.35% |
| Shares Change (QoQ) | 0.27% | 0.27% |
| Float | 28,070,800 | 37,097,900 |
| Shares Held by Insiders | 42.0% | 10.6% |
| Shares Held by Institutions | 0.01% | 63.5% |
Scores
| Measure | Nuo Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -10.21 | 1.95 |
| Piotroski F-Score | 3 | 5 |
Calculated by StockData from Nuo Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.